| Old Articles: <Older 7481-7490 Newer> |
|---|
 |
The Motley Fool
May 27, 2011
Seth Jayson |
A Hidden Reason Why Eli Lilly's Earnings Are Outstanding With both 12-month and quarterly CCC running better than average, Eli Lilly gets high marks in this cash-conversion checkup.   |
The Motley Fool
May 26, 2011
Andrew Tonner |
Does Agilent Technologies Deserve a Spot in Your Portfolio? Let's take a look at Agilent Technologies and some of its closest peers. |
The Motley Fool
May 26, 2011
Brian Orelli |
Intriguing, Potentially Lucrative, But Still Not Worth the Jump in Shares Elan sets up a drug development deal with Proteostasis. |
The Motley Fool
May 26, 2011
Brian Orelli |
Amylin Scores First in Court But it is still early innings. |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
The Motley Fool
May 26, 2011
Seth Jayson |
Are Hologic's Earnings Better Than They Look? With quarterly CCC doing better than average and the latest 12-month CCC coming in worse, Hologic gets a mixed review in this cash-conversion checkup. |
The Motley Fool
May 25, 2011
Brian Orelli |
Optimer's Upcoming FDA Decision: Memorable or Memorial? We'll know on Memorial Day, plus or minus a few days. |
The Motley Fool
May 25, 2011
Brian Orelli |
No Red Carpet for Medtronic's New CEO Omar Ishrak, Medtronic's newly-appointed CEO, looks like he has his work cut out for him trying to get the medical-device maker growing again. |
The Motley Fool
May 25, 2011
David Williamson |
Pay Attention to Shire The British ADHD medicine maker is busy making big moves. |
The Motley Fool
May 25, 2011
Brian Orelli |
Satisfying Clinical Trial Straightens Up Shares VIVUS' erectile dysfunction drug avanafil works. |
| <Older 7481-7490 Newer> Return to current articles. |
